血管内皮抑素抗肿瘤研究进展综述(3)
 |
| 第1页 |
参见附件。
[12] Moschos SJ,Odoux C,Land SR,et al.Endostatin plus interferon-[alpha]2b therapy for metastatic melanoma:a novel combination of antiangiogenic and immunomodulatory agents.Melanoma Res,2007,17(3):193-200.
[13] Kulke MH,Bergsland EK,Ryan DP,et al.Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.J Clin Oncol,2006,24:3555-3561.
[14] 杨林,王金万,汤仲明,等.重组人血管内皮抑制素Ⅰ期临床研究.中国新药杂志,2004,13:548-553.
[15] 杨林,王金万,孙燕,等.重组人血管内皮抑制素YH-16治疗晚期非小细胞肺癌的临床研究.中华肿瘤杂志,2006,28(2):138-141.
[16] 刘秀峰,秦叔逵,王琳,等.恩度与化疗联合治疗多种晚期恶性肿瘤的临床观察.临床肿瘤学杂志,2007,12(4):241-245.
[17] 蔡莉,孙立春,杨春雨,等.恩度联合化疗治疗中晚期非小细胞肺癌的疗效观察.中国实用内科杂志,2007,27(19):1541-1542.
[18] Celik I,Surucu O,Dietz C,et al.Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve.Cancer Res,2005,65:11044-11050.
[19] Kisker O,Becker CM,Prox D,et al.Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model.Cancer Res,2001,61(20):7669-7674.
[20] Rubin DB.The Radiation Biology of Vascular Endothelium.CRC Press,1998,1:1.
您现在查看是摘要介绍页，详见PDF附件。